Treatment Burnout in Crohn's Disease: A Patient Guide

There is a moment many of us living with Crohn's disease recognise and almost never say out loud: you look at the injection in your hand, or the pills on the counter, and feel nothing but tiredness about the whole thing. Treatment burnout in Crohn's disease is not laziness or a failure of willpower. It is a measurable, documented experience, and the research on it is far more sympathetic than the phrase "non-compliance" in your clinic notes.

Key Takeaways

• A 2025 systematic review of 79 studies and 36,589 people with IBD found non-adherence of 10.7 to 28.7 percent in high-quality self-report studies and 72 to 79 percent in refill data (1)
• In a study of 253 IBD patients, non-adherence was 24.4 percent in Crohn's disease, split almost evenly between intentional (16.3 percent) and unintentional (16.3 percent) (3)
• Depression, anxiety, and negative treatment beliefs all raised the likelihood of missed doses, and side effects were the main reason patients gave in interview studies (1)
• Treatment burnout in Crohn's disease shows up in the data as medication-related burden: among 86 people with ulcerative colitis, 45.3 percent reported a moderate level, highest in cost, medication concerns, and autonomy (6)
• A Cochrane review of 14 trials and 2,708 participants found patient education added to standard care is probably no better than standard care alone (5)
• Multicomponent interventions worked best across 17 adherence studies covering 7,073 IBD patients, so a combined plan beats more information (4)

What Treatment Burnout Actually Feels Like

Treatment burnout in Crohn's disease usually arrives as slow erosion rather than a dramatic decision. You dread injection day a little earlier each cycle. You quietly stretch the interval by a day, then two. You put off the blood draw. Nothing has broken, but the routine has stopped feeling like care and started feeling like a tax on being alive.

Researchers have measured it. A cross-sectional study of 86 people with ulcerative colitis used the Living with Medicines Questionnaire and found 45.3 percent had moderate medication-related burden (6). The heaviest domains were cost, concerns about the medication itself, and wanting the autonomy to vary the regimen (6). Practical difficulty physically taking the drug was not the top driver. The burden was about money, worry, and loss of control.

Burnout is not the same as giving up

Giving up is a conclusion. Burnout is a signal, and signals can be acted on. In our community we have seen people move from "I cannot do this any more" to a workable routine, not by trying harder, but by changing something concrete: the dosing interval, the delivery method, the cost, the reminder system, or the untreated anxiety underneath it. If injection dread is part of yours, that is its own well-studied problem, and our guide to needle anxiety and biologic injections covers techniques worth raising with your team rather than white-knuckling through.

How Common Is Skipping Crohn's Medication?

Skipping Crohn's medication is common rather than rare. A 2025 systematic review pooled 79 studies covering 36,589 people with IBD and found non-adherence of 10.7 to 28.7 percent in the highest-quality self-report studies, rising to 72 to 79 percent when measured through pharmacy refill records (1). Whichever end of that range you take, you are not unusual.

Why the numbers look so different depending on who you ask

Self-report under-captures missed doses: people forget what they forgot, and almost nobody enjoys telling the person managing their care that they have been skipping treatment. Refill data over-captures them, because a late refill is not always a missed dose. You may have stock at home, or have been in hospital, or have hit a prior authorisation delay that had nothing to do with your intentions.

The truth sits between the two, and the pattern matters more than the number. In a separate study of 253 IBD patients, non-adherence was 24.4 percent in Crohn's disease and 41.9 percent in ulcerative colitis (3). A useful habit when reading adherence statistics: check the measurement method before you believe the figure.

Intentional Versus Unintentional: Which One Is Yours?

This is the distinction that changes what you should actually do. In that 253-patient study, the Crohn's group split almost perfectly down the middle: 16.3 percent intentional non-adherence and 16.3 percent unintentional (3). Two different problems, equal in size, usually treated as one.

Intentional: a decision you made

Intentional non-adherence means you chose to skip, reduce, or stop. The 2025 review found the main reason patients gave in interview studies was side effects, alongside negative beliefs about the treatment and feeling well enough that the medication seemed unnecessary (1).

That last one matters especially in Crohn's. Maintenance therapy works by keeping you well, so its success removes the daily evidence that you need it. Remission can feel like proof you are fine without the drug, when it is usually proof the drug is working.

Unintentional: life got in the way

Unintentional non-adherence means you meant to take it and did not. The review identified forgetting, difficulty with organisation and planning, and medication accessibility problems as the drivers here (1).

A quick self-check. When you last missed a dose, was it closer to:

• "I decided not to take it", because of side effects, worry, or feeling well. That is the intentional pattern, and the fix is a conversation about the drug, the dose, or your concerns.
• "I meant to and it slipped", because you travelled, the refill did not arrive, or the pen was not in the fridge. That is the unintentional pattern, and the fix is systems.
• Both, in different weeks. Very common, and it means you need both halves of the plan.

A reminder app does nothing for side effects, and a side-effect conversation does nothing for a chaotic travel schedule. Matching the fix to the real barrier is the point.

Why Burnout Happens: Side Effects, Cost, Mood, and Beliefs

The 2025 review sorted risk factors into those that can be changed and those that cannot (1), and that sorting is where the hope lives. The most frequently identified modifiable risks were poor understanding of the disease or treatment, medication accessibility problems, and an individual's organisation and planning (1). Treatment type and regimen complexity also mattered, which makes "this regimen is too complicated for my life" a legitimate clinical point rather than a shortcoming to hide. Non-modifiable risks included limited finances, younger age, and female sex (1).

The mental health link

Depression, anxiety, and negative treatment beliefs or low mood all increased the likelihood of non-adherence (1). This is one of the most actionable findings in the literature, because mood is treatable. If your burnout sits on top of untreated anxiety or depression, treating the mood is part of the medication plan rather than a detour from it. Our guide to CBT for Crohn's disease covers what that therapy involves in IBD specifically.

The money link

Cost was the highest-scoring burden domain in the Living with Medicines study (6), and limited finances appeared as a risk factor in the 2025 review (1). This varies enormously by country: in some systems maintenance biologics arrive at your door at no cost to you, and in others each cycle means copays, deductibles, or a fight with an insurer. If cost or access is your barrier, the fight is administrative rather than medical, and it is winnable more often than people expect. Our walkthrough of prior authorisation and appeals for Crohn's disease covers how to push back on a denial.

What Happens If You Stop Maintenance Treatment

The risk here is real, and the Crohn's-specific evidence is thinner than you might assume. In a prospective study of 99 people with quiescent ulcerative colitis on maintenance mesalamine, those refilling less than 80 percent of their prescriptions had more than a fivefold higher risk of clinical relapse (hazard ratio 5.5, 95 percent confidence interval 2.3 to 13) (2).

The clearest evidence comes from ulcerative colitis

The honest limitation: that study was in ulcerative colitis, on mesalamine, two decades ago. It is not a Crohn's cohort on a modern biologic. It demonstrates the principle that maintenance adherence protects remission, but it does not give you a Crohn's-specific number.

What we can say about Crohn's is what relapse tends to cost: a corticosteroid course with its own side-effect load, a risk of losing response to a drug that had been working (particularly with biologics, where intermittent exposure is associated with antibody formation), and the possibility of moving to a different drug class sooner than you otherwise would, which narrows the options left for the decades ahead.

None of that is meant to frighten you, and fear is not a treatment plan. If the fear of flaring is already daily background noise for you, our guide to the fear of flare in Crohn's disease addresses that directly.

The practical point is narrower than "never stop." Stopping should be a planned conversation with your IBD team rather than a silent decision made alone at 11pm. De-escalation is sometimes a reasonable, evidence-informed choice, and your gastroenterologist can help you weigh it, monitor you, and keep a re-start plan ready. A planned stop is a different thing from quietly running out.

What Helps, and How to Raise It With Your IBD Team

Education alone is not the answer

A Cochrane review of 14 randomised trials and 2,708 participants concluded that patient education added to standard care is probably of no benefit compared with standard care alone, for disease activity or quality of life (5).

That finding is liberating. If you have read the leaflets, understood the mechanism, and are still burnt out, the problem is not an information deficit. You are not failing to understand. You are carrying a burden that information does not lift.

Strategies worth trying

What worked was combination. A systematic review of 17 adherence interventions across 7,073 IBD patients found 12 significantly improved adherence, and that multicomponent interventions were the most successful (4). The 2025 review's own recommendations were simpler regimens, better accessibility, and reminders or cues to reduce forgetting (1). Together that points to a plan with several moving parts:

1. Simplify the regimen. Ask whether a longer dosing interval, a different formulation, or fewer daily doses is clinically possible.
2. Fix accessibility. Home delivery, auto-refill, support programmes, and a standing refill reminder remove whole categories of missed doses.
3. Build the cue. Tie the dose to something that already happens daily, keep organisers visible, and set a recurring alarm for injection day.
4. Name the side effects out loud. They were the top intentional driver (1), are often manageable, and are sometimes the reason to switch drugs.
5. Treat the mood. Where depression or anxiety is part of this, treating it is part of treating the adherence problem (1).
6. Plan for travel. Refrigerated biologics and broken routines are a predictable failure point, so prepare before the trip rather than during it.

Opening the conversation

Appointments are short, and the reflex answer to "how is the treatment going?" is "fine." Burnout rarely survives that exchange. Bring the specific barrier instead: "I have missed three doses this year because of the fatigue for two days afterwards." Or "I have been dreading the injections and stretched the interval twice." Or "the cost is the problem, not the medication."

Then ask directly about the levers your team controls: simpler regimens, longer dosing intervals, alternative formulations, home delivery, nurse support programmes, and any patient assistance that applies where you live. Regimen complexity is a documented risk factor (1), which makes asking for a simpler one a clinical request rather than a complaint.

Resources Worth Exploring

The 2025 review named forgetting, organisation, and accessibility as modifiable drivers of unintentional missed doses, with reminders and cues as a recommended response (1). For readers whose pattern is the unintentional one, these two tool categories map onto that evidence.

• Ezy Dose Weekly 7-Day AM/PM Pill Organizer - a large-compartment weekly organiser with separate morning and evening sections, which makes a missed dose visible the same day rather than at the end of the week. This is not a medical recommendation. Discuss with your healthcare provider before trying any new product or protocol.

• ChillMED Insulin Cooler Travel Case - an insulated case with a reusable ice pack, designed for injection pens and useful for keeping refrigerated biologics such as adalimumab or ustekinumab within range while travelling. Check your own product's storage and temperature-excursion instructions, since these vary by medication and country. This is not a medical recommendation. Discuss with your healthcare provider before trying any new product or protocol.

Frequently Asked Questions

Is treatment burnout in Crohn's disease a real medical concept?

Yes. Medication-related burden is measured with validated instruments such as the Living with Medicines Questionnaire. In 86 people with ulcerative colitis, 45.3 percent reported moderate medication-related burden, scoring highest in the cost, medication-concern, and autonomy domains (6). The experience is documented in the literature, not only in patient forums.

How many people with Crohn's disease actually skip their medication?

It depends on how it is measured. A 2025 systematic review of 79 studies and 36,589 people with IBD found 10.7 to 28.7 percent non-adherence in high-quality self-report studies and 72 to 79 percent in refill-based studies (1). A separate 253-patient study found 24.4 percent in Crohn's disease specifically (3).

What happens if I stop my maintenance medication while I feel well?

Feeling well is often evidence the treatment is working rather than evidence you no longer need it. In 99 people with quiescent ulcerative colitis on mesalamine, refilling under 80 percent of prescriptions carried more than a fivefold higher relapse risk (2). That study was in ulcerative colitis, so treat it as the principle rather than a Crohn's figure. In Crohn's, relapse can also mean steroid courses and a risk of losing response to a drug that was working.

Will reading more about my medication help me stick with it?

Probably not on its own. A Cochrane review of 14 randomised trials and 2,708 participants found patient education added to standard care is probably no better than standard care alone (5). A review of 17 interventions in 7,073 IBD patients found multicomponent approaches most successful (4), meaning reminders plus a cost plan plus a side-effect conversation.

Can anxiety or depression be the reason I keep missing doses?

It can be a significant part of it. The 2025 review found depression, anxiety, and negative treatment beliefs or low mood all increased the likelihood of non-adherence (1). If this fits, treating the mood is part of the adherence plan rather than a separate issue, and therapies such as CBT have been studied in IBD populations.

How do I tell my gastroenterologist I have been skipping doses?

Lead with the barrier rather than the behaviour. "I have missed doses because of the fatigue afterwards" or "the cost has become the problem" gives your team something to act on. Non-adherence reached roughly one in four people with Crohn's in some cohorts (3), so this is a familiar conversation, and accessibility and regimen complexity are risk factors they can address (1).

The Bottom Line

If you are burnt out on your Crohn's treatment, stop treating it as a character problem and start treating it as a solvable one with a named barrier. Work out whether your pattern is intentional, unintentional, or both, then bring that barrier to your next appointment instead of saying treatment is fine. More information alone probably will not fix this (5), and combined practical interventions often do (4). Burnout is a signal that something in the plan needs changing, not a verdict on you.

References

1. Chan W, et al. Medication Non-Adherence in Inflammatory Bowel Disease: A Systematic Review Identifying Risk Factors and Opportunities for Intervention. 2025. View on PubMed
2. Kane S, et al. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. The American Journal of Medicine, 2003. View on PubMed
3. Beliefs About Medicines and Adherence to Treatment in Turkish Patients with Inflammatory Bowel Disease. 2022. View on PubMed
4. Interventions to improve medication adherence in inflammatory bowel disease: A systematic review. 2022. View on PubMed
5. Patient education interventions for the management of inflammatory bowel disease. Cochrane Database of Systematic Reviews, 2023. View on PubMed
6. Medication-related burden among Iraqi patients with ulcerative colitis: a cross-sectional study. 2024. View on PubMed